10 Stocks Fall Behind Amid Market Optimism

4. Revelation Biosciences Inc. (NASDAQ:REVB)

Revelation Biosciences dropped by 13.28 percent on Wednesday to close at $3.2 apiece as investors sold off positions for higher-yielding assets amid the lack of fresh developments.

In recent news, REVB announced positive results in the clinical trials for REVTx-300 and  REVTx-100 for the potential treatment of acute and chronic organ disease and the prevention and treatment of infection.

According to the company, the studies, under what it named the Gemini project, showed a reduction in the inflammatory response in human peripheral blood mononuclear cells (PBMCs) that were exposed to clinically relevant molecules on inflammation.

Human PBMCs were primed with either Gemini or placebo followed by a challenge with clinically relevant promoter molecules of inflammation including high mobility box protein-1 (HMGB-1) and lipopolysaccharide (LPS) in vitro.